Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Curvebeam AI Ltd. ( (AU:CVB) ) has provided an update.
CurveBeam AI Limited has issued 62,222,223 fully paid ordinary shares at $0.09 per share, raising $5.6 million through a Tranche 1 Placement under ASX Listing Rules. This strategic move enhances CurveBeam AI’s financial capacity, potentially strengthening its market position in the medical imaging industry by supporting further development and distribution of its innovative CT scanning technology.
The most recent analyst rating on (AU:CVB) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.
More about Curvebeam AI Ltd.
CurveBeam AI Limited develops, manufactures, and sells specialized medical imaging CT scanners, along with AI SaaS-based clinical assessment solutions to aid medical practitioners in managing musculoskeletal conditions. The company’s flagship product, HiRise™, offers both weight-bearing and traditional non-weight-bearing CT scans, providing advantages over traditional CT or MRI devices. CurveBeam AI operates with over 70 employees, with its corporate office in Melbourne, Australia, and global operations headquarters in Hatfield, Pennsylvania, USA.
Average Trading Volume: 301,522
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$39.56M
For a thorough assessment of CVB stock, go to TipRanks’ Stock Analysis page.